+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
AKUMS

Akums Drugs & Pharmaceuticals Share Price

 
Near 52W High of ₹714.70

 

Akums Drugs & Pharmaceuticals live price: ₹687.30. It opened at ₹688 vs previous close ₹696; intraday high/low: ₹693/₹678. The 50 & 200 DMA stand at ₹618.50/₹543.80.

Akums Drugs & Pharmaceuticals Performance

  • Today's Low
  • ₹678
  • Today's High
  • ₹693
  • 52 Week Low
  • ₹409
  • 52 Week High
  • ₹715
  • Open Price₹688
  • Previous Close₹696
  • Volume151,167
  • 50 DMA₹618.50
  • 100 DMA₹573.30
  • 200 DMA₹543.80

Akums Drugs & Pharmaceuticals Chart

Investment Returns

  • Over 1 Month + 12.79%
  • Over 3 Month + 33.64%
  • Over 6 Month + 61.79%
  • Over 1 Year + 29.63%

Smart Investing Starts Here Start SIP with Akums Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Akums Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 42.4
  • PEG Ratio
  • -1.7
  • Market Cap Cr
  • 10,818
  • P/B Ratio
  • 3.3
  • Average True Range
  • 23.6
  • EPS
  • 16.2
  • Dividend Yield
  • 0.4
  • MACD Signal
  • 25.4
  • RSI
  • 63.25
  • MFI
  • 77.17

Latest Stock News Updates

Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Acquisition

Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Acquisition of Oriflame India''s Manufacturing Business

Akums Drugs and Pharmaceuticals Ltd - 544222 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

Voting Results and Scrutinizer''s Report of the 22nd Annual General Meeting

Akums Drugs and Pharmaceuticals Ltd - 544222 - Shareholder Meeting / Postal Ballot-Outcome of AGM

Proceedings of the 22nd Annual General Meeting of the Company

Akums Drugs & Pharmaceuticals Financials

Akums Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹687.30
-8.6 (-1.24%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 14
  • 20 Day
  • ₹664.50
  • 50 Day
  • ₹618.50
  • 100 Day
  • ₹573.30
  • 200 Day
  • ₹543.80

Resistance and Support

686.1 Pivot Speed
  • R3 708.90
  • R2 700.90
  • R1 694.10
  • S1 679.30
  • S2 671.30
  • S3 664.50

Akums Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-14 Audited Results & Final Dividend
2026-02-13 Quarterly Results
2025-11-13 Quarterly Results
2025-08-08 Quarterly Results
2025-05-26 Audited Results
Date Purpose Remarks
2026-07-03 FINAL Rs.1.00 per share(50%)Final Dividend
2026-07-03 SPECIAL Rs.2.00 per share(100%)Special Dividend
View Akums Drugs & Pharmaceuticals Dividend History Arrow

Akums Drugs & Pharmaceuticals Shareholding Pattern

75.26%
9.77%
6.67%
3.67%
1.91%

About Akums Drugs & Pharmaceuticals

Akums Drugs & Pharmaceuticals is engaged in contract manufacturing which involves manufacturing of pharmaceutical formulations and specializes in developing new formulations, undertaking bio equivalence studies, clinical trials, obtaining Drug Controller General of India's (DCGI) approval for manufacturing and marketing new Fixed Dose Combinations (FDCs) & molecules and thereby offering new formulations with Company's own technology to its customers under their brand names.(Source : AR-PDF:202603-01 Pg No:223) View More
  • NSE Symbol
  • AKUMS
  • BSE Symbol
  • 544222
  • ISIN
  • INE09XN01023

Similar Stocks to Akums Drugs & Pharmaceuticals

Akums Drugs & Pharmaceuticals FAQs

Akums Drugs & Pharmaceuticals share price is ₹687 As on 26 July, 2026 | 23:23

The Market Cap of Akums Drugs & Pharmaceuticals is ₹10817.7 Cr As on 26 July, 2026 | 23:23

The P/E ratio of Akums Drugs & Pharmaceuticals is 42.4 As on 26 July, 2026 | 23:23

The PB ratio of Akums Drugs & Pharmaceuticals is 3.3 As on 26 July, 2026 | 23:23

The 52 week High & Low of Akums Drugs & Pharmaceuticals is ₹714.7/₹409.3 respectively As on 26 July, 2026 | 23:23

Open FREE Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23